Each year in Europe more than 550,000 patients are diagnosed with breast cancer, of whom 70% have estrogen receptor (ER)-positive disease¹; more than 147,000 breast cancer patients in Europe die annually from the disease²

- Chaque année en Europe, plus de 550 000 patientes reçoivent un diagnostic de cancer du sein, dont 70 % ont des récepteurs d'œstrogènes positifs¹ ; plus de 147 000 patientes atteintes d'un cancer du sein en Europe meurent chaque année de cette maladie².

FLORENCE, le 6 juillet 2023 - Hier soir, la grande finale de la XXVIIe édition des Menarini International Fair Play Awards a été chaleureusement accueillie par plus d'un millier de spectateurs au Théâtre Romain de Fiesole. L'événement, organisé par la Menarini Fair Play Fondation et axé sur la culture du fair-play et du respect dans le sport, s'est achevé pour la première fois sur cette magnifique scène.

FLORENCE, 2 juillet 2023 - Le comptParmi les invités figureront un certain nombre d'ambassadeurs du Fair Play Menarini renommés qui ont écrit l'histoire du sport internationale à rebours a commencé pour la XXVIIe édition des Fair Play Menarini International Awards. Demain, lundi 3 juillet, l'édition 2023 de l'événement, dédié aux valeurs sportives, à l'éthique, au fair-play et au respect débutera officiellement dans la ville de Florence avec le très attendu talk-show de la journée

ROME, June 19 th , 2023 - The winners of the XXVII annual Fair Play Menarini International Awards are no longer a secret. This morning at the CONI Hall of Honour, a press conference was held to present the 2023 edition of the awards, scheduled from July 3 rd to 5 th in Florence and Fiesole. In the presence of Giovanni Malagò, President of the Italian National Olympic Committee (CONI), the Fair Play Menarini Foundation unveiled the list of this year’s winners to be celebrated at the event which has promoted the values of ethics, loyalty and respect through the example of Italian and international sport legends since 1997.

Artiste à succès, interprète sensible de la culture de son époque, et auteur d'œuvres d'une importance extraordinaire, Sandro Botticelli était un maître de la beauté. Avec ses "Vénus", il a inconsciemment établi un canon de perfection qui reflète étroitement celui de notre époque moderne. Pourtant, il était une figure mystérieuse et tourmentée : malgré sa réputation intemporelle, ses tableaux cachent encore des mystères difficiles à dévoiler. Après soixante ans, Sandro Botticelli revient dans la série d'art du groupe Menarini avec une monographie inédite présentée à Florence dans la Salle Apollo du Palazzo Pucci, en présence de l'auteure Cristina Acidini, ancienne conservatrice des musées d'art de Florence et aujourd'hui présidente de l'Opéra de Santa Croce et d'autres prestigieuses institutions florentines.

FLORENCE, 13 avril 2023 - Les préparatifs sont déjà en cours pour le Prix International Fair Play Menarini. Cette année, l'événement rend hommage aux athlètes démontrant des valeurs telles que, l'éthique, la loyauté et le respect dans le sport et dans la vie. Cette XXVIIe édition accueillera des légendes du sport international pendant une cérémonie de trois jours à Florence et à Fiesole.

Stemline Therapeutics, a subsidiary of Menarini Group, Receives U.S. FDA Approval for ORSERDUTM (elacestrant) as the First and Only Treatment Specifically Indicated for Patients with ESR1 Mutations in ER+, HER2- Advanced or Metastatic Breast Cancer

Menarini Group’s Elacestrant Marketing Authorization Application Accepted for Review by the European Medicines Agency (EMA) for the Treatment of ER+/HER2- Advanced or Metastatic Breast Cancer

FLORENCE, Italy and NEW YORK, NY, August 11, 2022 -- The Menarini Group (“Menarini”), a privately held Italian pharmaceutical and diagnostics company, and Stemline Therapeutics (“Stemline”), a wholly-owned subsidiary of Menarini Group, today announced that the U.S. Food and Drug Administration (FDA) has accepted the Company’s New Drug Application (NDA) for elacestrant, an investigational selective estrogen receptor degrader (SERD), for patients with ER+/HER2- advanced or metastatic breast cancer. The FDA has granted the application Priority Review and assigned a PDUFA date of February 17, 2023.

NEWTON, Mass.and FLORENCE, Italy, – July 21, 2022 – Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, and the Menarini Group ("Menarini"), a privately-held, leading international pharmaceutical company, today announced that the European Commission (EC) has granted Marketing Authorisation for NEXPOVIO® (selinexor), a first-in-class, oral exportin 1 (XPO1) inhibitor

Menarini chooses Italy for its new €150 million manufacturing site. Not only will the new plant be the most modern and among the largest of the Group, but it will also be a sign of Italy’s strong desire to relaunch itself. The decision to interrupt the search for the most economically attractive international location and the choice to favour Italy matured during the extremely difficult period of the lockdown, when the tragic consequences of the pandemic on the Italian economy began to be evident.

Florence, Italy and Boston, Mass., June 6, 2022 - The Menarini Group (“Menarini”) and Radius Health, Inc. (“Radius”) (NASDAQ: RDUS) (collectively, the “Companies”) today announced the presentation at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting of data from the EMERALD phase 3 clinical trial (NCT03778931). In a non-pre-specified subgroup analysis of patients with ER+/HER2? metastatic breast cancer (mBC) without prior chemotherapy in the metastatic setting, elacestrant significantly prolonged progression-free survival (PFS) compared to standard of care (SOC) endocrine therapy.

Florence, Italy and Boston, Mass., October 20, 2021– the Menarini Group (“Menarini”) and Radius Health, Inc. (“Radius”) (NASDAQ: RDUS) (collectively, the “Companies”) today announced positive topline results from the EMERALD study.

Mot d'ordre : faire parler de l'art aux jeunes générations. Après le succès de “Pills of Arts” avec 18 millions de vues dans le monde, Menarini lance la version "junior", dans laquelle de jeunes experts en art répondent aux questions, et parfois aux curiosités inattendues, que les enfants peuvent avoir sur les grandes œuvres de la Renaissance italienne. Une façon plus amusante de voir l'art, les grands maîtres eux-mêmes auraient approuvé !

FLORENCE, November 13th, 2020 – The Menarini Group, a privately held Italian pharmaceutical and diagnostics company, announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion on the approval of ELZONRIS (tagraxofusp) as monotherapy for the first-line treatment of adult patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN), an aggressive hematologic malignancy with dismal outcomes.The positive opinion from the CHMP was based onthe largest prospective clinical trial ever conducted in patients with treatment-naïve or previously-treated BPDCN.

In a recent interview with ANSA, the CEO of the Menarini Group, Elcin Barker Ergun commented : “As we go through one of the biggest health challenges in this century, Menarini Group continues to be a key actor in the fight against the pandemic by bringing crucial Covid-19 tests to market and recently extending into therapeutic solutions, joining forces with Tuscany Life Sciences to bring an antibody against Covid-19. We must also do everything possible to anticipate and prevent other crises such as the key threat from AMR where if not acted in a decisive way today, can turn into an even larger crisis than Covid-19 in coming years.”

Menarini Group and Radius Health Announce Global License Agreement for the Development and Commercialization of Elacestrant

FLORENCE – June 10, 2020 – Menarini Group, a privately held Italian pharmaceutical and diagnostics company, today announced that is has successfully completed the acquisition of Stemline Therapeutics Inc., a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics (Nasdaq: STML), for an aggregate cash consideration up to $677 million on a fully diluted basis.

Menarini chooses Italy for its new €150 million manufacturing site. Not only will the new plant be the most modern and among the largest of the Group, but it will also be a sign of Italy’s strong desire to relaunch itself. The decision to interrupt the search for the most economically attractive international location and the choice to favour Italy matured during the extremely difficult period of the lockdown, when the tragic consequences of the pandemic on the Italian economy began to be evident.

FLORENCE and NEW YORK – May 4, 2020 – Menarini Group, a privately held Italian pharmaceutical and diagnostics company, and Stemline Therapeutics Inc., a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics, (Nasdaq: STML) today announced a definitive agreement under which Menarini Group will acquire Stemline in a transaction valued up to $677 million.